Sharp Therapeutics Corp.
SHRX.V
TSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -61.63% | 7.48% | -112.24% | 12.49% | 25.38% |
| Total Depreciation and Amortization | -7.12% | 10.00% | -1.99% | 48.58% | -3.11% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 179.99% | -148.30% | 407.55% | -163.19% | -154.68% |
| Change in Net Operating Assets | 252.10% | 1,237.70% | 604.49% | -204.49% | -166.77% |
| Cash from Operations | 13.44% | -3.54% | -33.16% | -102.91% | -128.87% |
| Capital Expenditure | -- | -- | -- | 100.00% | 100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | 135.17% | 135.17% |
| Total Debt Issued | 63.16% | -64.77% | -- | -100.00% | 3,050.31% |
| Total Debt Repaid | 51.42% | 52.82% | 54.21% | -118.40% | -118.40% |
| Issuance of Common Stock | -99.45% | -49.16% | -53.82% | 340.65% | 158.32% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | 200.00% | -- |
| Cash from Financing | -81.51% | -50.34% | -65.46% | 244.89% | 181.45% |
| Foreign Exchange rate Adjustments | -626.14% | 28.14% | -706.56% | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -200.00% | 200.00% |
| Net Change in Cash | -204.43% | -181.61% | -181.35% | 2,291.51% | 4,039.86% |